| Fri, 18 Jun 2021 09:15:48: | FDA rejects Orphazyme's rare disease drug, continuing wild ride for Danish meme stock
|
| Fri, 18 Jun 2021 08:21:36: | Bristol Myers pays $650M for rights to Eisai's phase 1 ADC
|
| Thu, 17 Jun 2021 20:22:32: | Chutes & Ladders—Ex-FDA chief Hahn joins Moderna backer
|
| Thu, 17 Jun 2021 14:20:09: | Targeting treatment-resistant BRCA-mutated tumors via the newly discovered POLQ pathway
|
| Thu, 17 Jun 2021 11:40:29: | Targeting 'enabler cells' to stop the spread of triple-negative breast cancer
|
| Thu, 17 Jun 2021 10:01:39: | Lilly helps Circle round up $66M for intractable target R&D
|
| Thu, 17 Jun 2021 09:15:19: | Biogen's $300M bet on Alzheimer's tau drug snapped up from Bristol Myers flames out in phase 2
|
| Wed, 16 Jun 2021 21:09:35: | CureVac's first-gen COVID-19 vaccine misses the mark with 47% efficacy, as share price halves in after-hours trading
|
| Wed, 16 Jun 2021 12:29:55: | New COVID-19 approach exploits protein response in human cells to combat virus
|
| Wed, 16 Jun 2021 12:13:06: | Molecular Partners prices $64M IPO, falling short of original goal
|
| Wed, 16 Jun 2021 10:10:22: | Kahr reels in $47M to fund CD47 trial, work on TIGIT prospect
|
| Tue, 15 Jun 2021 16:49:07: | Evotec wants to prevent the next COVID-19 crisis, and you could help
|
| Tue, 15 Jun 2021 09:53:38: | VectorY raises $38M to develop Alzheimer's, ALS gene therapies
|
| Tue, 15 Jun 2021 09:13:59: | AstraZeneca's COVID-19 antibody combination fails post-exposure prevention trial
|
| Mon, 14 Jun 2021 15:20:26: | Diabetes mainstay metformin tamps down lung inflammation in COVID models
|
| Mon, 14 Jun 2021 09:39:02: | EHA: Epizyme's first-in-class multiple myeloma drug candidate inhibits tumors in mice
|
| Mon, 14 Jun 2021 08:56:29: | GSK pays iTeos $625M upfront to join Merck, Roche and the rest in TIGIT immuno-oncology race
|
| Mon, 14 Jun 2021 07:50:59: | Novavax COVID-19 vaccine hits 90% efficacy in pivotal U.S. trial
|
| Fri, 11 Jun 2021 10:37:19: | Sanofi's treatment for rare anemia hits goal in 2nd phase 3
|
| Fri, 11 Jun 2021 08:52:37: | Harvard's Kesselheim quits AdComm over FDA's Aduhelm approval
|
| Fri, 11 Jun 2021 08:24:51: | Eli Lilly, Roche's Alzheimer's prospects, including flops, boosted in light of FDA's Aduhelm approval: analysts
|
| Thu, 10 Jun 2021 19:02:17: | Chutes & Ladders—FDA nod for Biogen's Aduhelm sees trio of AdComm members hit the exit
|
| Thu, 10 Jun 2021 13:18:58: | Acumen rides aducanumab, amyloid and Alzheimer's waves on its IPO voyage
|
| Thu, 10 Jun 2021 12:05:11: | Kurome raises $15M to overcome adaptive resistance in leukemia
|
| Thu, 10 Jun 2021 09:55:28: | AdComm exodus: 2nd expert quits over FDA approval of Biogen's Aduhelm
|
